Skip to main content
Midas Edge

UTAH MEDICAL PRODUCTS INC

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Unregistered Sales of Equity Securities and Use of Proceeds

The following table details purchases by UTMD of its own securities during 2Q 2026.

ISSUER PURCHASES OF EQUITY SECURITIES

Period(a) Total number of shares purchased (1)(b) Average price paid per share (1)(c) Total number of shares purchased as part of publicly announced plans or programs (1)(d) Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)
04/01/26 - 04/30/26--N/AN/A
05/01/26 – 05/31/261,00063.70N/AN/A
06/01/26 – 06/30/2620766.02N/AN/A
Total1,20764.10N/AN/A

1)None of the shares were purchased as part of a publicly announced specific plan, and all were purchased on the open market.

The frequency of UTMD’s open market share repurchases depends on the availability of sellers and the price of the stock. The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD’s continuing and long-term pattern of open market share repurchases since 1992.

The purpose of UTMD’s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business. UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.